ASCO Breakthrough: A Global Summit for Oncology Innovators
Deep Learning Assists in Detection of Lung Nodule Locations, Characteristics
A computer-aided diagnosis system using deep-learning analysis to detect lung lesion locations and quantitatively characterize the lesions on computed tomography (CT) images offered a fast and conveni...
Targeted Methylation Sequencing Assay May Provide New Tool for Cancer Detection Across Stages and Tissues of Origin
A study by Geoffrey R. Oxnard, MD, and colleagues using bisulfite sequencing of plasma cell-free DNA to identify methylomic signatures for multicancer detection and tissue-of-origin determination fou...
ASCO Breakthrough: Breast Cancer Gene-Expression Signature May Help Predict Recurrence Postradiotherapy
Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the ti...
ASCO Breakthrough: Effect of ATM Mutations on Response to Radiotherapy
Somatic mutations of DNA damage repair genes like ATM and BRCA1 or BRCA2 may result in poor disease prognosis and chemotherapy resistance. However, a study by Lee et al presented at ASCO Breakthrough:...
ASCO Breakthrough: Computer-Aided Diagnosis System for Detecting Lung Nodule Locations and Characteristics
A computer-aided diagnosis system using deep-learning analysis to detect lung lesion locations and quantitatively characterize the lesions on computed tomography (CT) images offered a fast and conveni...
ASCO Breakthrough: Targeted Methylation Sequencing Assay May Provide New Tool for Cancer Detection Across Stages and Tissues of Origin
A study by Oxnard et al using bisulfite sequencing of plasma cell-free DNA to identify methylomic signatures for multicancer detection and tissue of origin found the assay achieved accurate detection ...
ASCO Breakthrough: Blood-Based Screening Assay With a Novel Multivariate Cancer Risk Score Model
A novel multivariate cancer risk score model demonstrated 60% sensitivity at 98.5% specificity. These findings demonstrate that a blood-based cancer screening assay with a novel risk score model may b...
